NTRK2 and neoplasm: Anlotinib plays a critical anti-tumor role of the epithelial–stroma interaction, mediated by lactate/BDNF/TRKB signaling in gastric cancer resistance [22] and the anti-tumor activity of anlotinib in oral squamous cell carcinoma involved in the suppression of mitochondrial respiration via NOX5-mediated redox imbalance and the AKT/eIF2α pathway [23].